Liver Cancer - Pipeline Review, H2 2012


#138045

120pages

Global Markets Direct

$ 2500

In Stock


Liver Cancer Pipeline Review, H2 2012

Global Markets Directs, 'Liver Cancer Pipeline Review, Global Markets Directs, 'Liver Cancer Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Liver Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Liver Cancer. 

Liver Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Liver Cancer.
  • A review of the Liver Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Liver Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Liver Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Liver Cancer pipeline depth and focus of Indication therapeutics. 
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. 
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Liver Cancer Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Liver Cancer 11
Liver Cancer Therapeutics under Development by Companies 13
Liver Cancer Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 22
Comparative Analysis 22
Mid Clinical Stage Products 23
Comparative Analysis 23
Early Clinical Stage Products 24
Comparative Analysis 24
Discovery and Pre-Clinical Stage Products 25
Comparative Analysis 25
Liver Cancer Therapeutics Products under Development by Companies 26
Liver Cancer Therapeutics Products under Investigation by Universities/Institutes 28
Companies Involved in Liver Cancer Therapeutics Development 34
Bristol-Myers Squibb Company 34
F. Hoffmann-La Roche Ltd. 35
Eli Lilly and Company 36
Tekmira Pharmaceuticals Corp. 37
Bavarian Nordic A/S 38
Kowa Company, Ltd. 39
MDRNA, Inc. 40
Pfizer Inc. 41
Silence Therapeutics plc. 42
MultiCell Technologies, Inc. 43
Northwest Biotherapeutics, Inc. 44
OXiGENE, Inc. 45
Curis, Inc. 46
Alnylam Pharmaceuticals, Inc 47
Transgene SA 48
Immuron Limited 49
Synta Pharmaceuticals Corp. 50
CrystalGenomics, Inc. 51
Chipscreen Biosciences Ltd 52
ERYtech Pharma 53
Provecs Medical GmbH 54
Jennerex Biotherapeutics, Inc. 55
Advenchen Laboratories, LLC 56
Onconova Therapeutics, Inc 57
MolMed S.p.A. 58
China Medical System Holdings Limited 59
Welichem Biotech Inc. 60
Oncolys BioPharma Inc. 61
Immunocore Limited. 62
Sirnaomics, Inc. 63
Viventia Biotechnologies Inc. 64
TRACON Pharmaceuticals, Inc. 65
KAHR medical Ltd. 66
Keystone Nano, Inc. 67
EOS S.p.A. 68
IkerChem S.L. 69
Liver Cancer Therapeutics Assessment 70
Assessment by Monotherapy Products 70
Assessment by Combination Products 71
Assessment by Route of Administration 72
Assessment by Molecule Type 74
Drug Profiles 76
peretinoin - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Carboplatin + Cisplatin + Doxorubicin Hydrochloride - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Cisplatin + Doxorubicin Hydrochloride - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Oxaliplatin + Capecitabine - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
tyroserleutide - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Oxaliplatin + Capecitabine + Cetuximab - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 84
Cisplatin + Doxorubicin + Mitomycin C + Sorafenib - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Xelox + Bevacizumab - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
TACE + Sunitinib Malate - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Doxorubicin + Mitomycin + Cisplatin - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 90
Cisplatin + Doxorubicin + Fluorouracil + Irinotecan + Vincristine - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Cisplatin + Doxorubicin + Fluorouracil + Vincristine - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
cytokine-induced killer cell (CIK) - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Gemcitabine + Capecitabine - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Gemcitabine Hydrochloride + Oxaliplatin - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Sunitinib + Chemoembolization - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Gemox 85 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Liver Cancer Therapeutics Drug Profile Updates 101
Liver Cancer Therapeutics Discontinued Products 102
Liver Cancer Therapeutics - Dormant Products 103
Liver Cancer Product Development Milestones 110
Featured News & Press Releases 110
Jun 04, 2012: Alnylam Presents Results From Phase I Extension Study Of ALN-VSP At ASCO 2012 Annual Meeting 110
May 22, 2012: Mirna Presents Updates On Development Program For miR-34 At Two Upcoming Conferences 111
May 16, 2012: MultiCell Technologies Announces Positive Preclinical Results For MCT-465 In Primary Liver Cancer In Vitro Models 112
May 16, 2012: MultiCell Technologies To Present Positive Preclinical Results For MCT-485 In Primary Liver Cancer In Vitro Models 113
Apr 04, 2012: Peregrine Presents Promising Clinical Data On Bavituximab In Breast And Liver Cancer Studies At AACR Annual Meeting 113
Mar 14, 2012: Tekmira Provides Update On Progress In USPTO Patent Interference Proceedings Related To Alnylam's ALN-VSP 115
Feb 13, 2012: Celsion Announces First Patient Enrolled In Phase II Study Of ThermoDox In Combination With RFA In Colorectal Liver Metastases 115
Jan 10, 2012: Clinical Study Confirms Benitec's Gene-silencing Technology Is Safe And Effective In Fang Vaccine 116
Nov 07, 2011: Transgene And Jennerex Announce Final Data At AASLD From JX594/TG6006 Randomized Phase II Clinical Trial Showing Statistically Significant Survival Benefit In Patients With Advanced Liver Cancer 117
Nov 02, 2011: Jennerex To Present Final Survival Data From Phase II Clinical Trial Of JX-594 In Advanced Liver Cancer At American Association For Study Of Liver Diseases Annual Meeting 118

Appendix 119
Methodology 119
Coverage 119
Secondary Research 119
Primary Research 119
Expert Panel Validation 119
Contact Us 120
Disclaimer 120

Number of Products Under Development for Liver Cancer, H2 2012 11
Products under Development for Liver Cancer Comparative Analysis, H2 2012 12
Number of Products under Development by Companies, H2 2012 14
Number of Products under Development by Companies, H2 2012 (Contd..1) 15
Number of Products under Development by Companies, H2 2012 (Contd..2) 16
Number of Products under Investigation by Universities/Institutes, H2 2012 18
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 19
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 21
Comparative Analysis by Late Stage Development, H2 2012 22
Comparative Analysis by Mid Clinical Stage Development, H2 2012 23
Comparative Analysis by Early Clinical Stage Development, H2 2012 24
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 25
Products under Development by Companies, H2 2012 26
Products under Investigation by Universities/Institutes, H2 2012 28
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 29
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 30
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 31
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 32
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 33
Bristol-Myers Squibb Company, H2 2012 34
F. Hoffmann-La Roche Ltd., H2 2012 35
Eli Lilly and Company, H2 2012 36
Tekmira Pharmaceuticals Corp., H2 2012 37
Bavarian Nordic A/S, H2 2012 38
Kowa Company, Ltd., H2 2012 39
MDRNA, Inc., H2 2012 40
Pfizer Inc., H2 2012 41
Silence Therapeutics plc., H2 2012 42
MultiCell Technologies, Inc., H2 2012 43
Northwest Biotherapeutics, Inc., H2 2012 44
OXiGENE, Inc., H2 2012 45
Curis, Inc., H2 2012 46
Alnylam Pharmaceuticals, Inc, H2 2012 47
Transgene SA, H2 2012 48
Immuron Limited, H2 2012 49
Synta Pharmaceuticals Corp., H2 2012 50
CrystalGenomics, Inc., H2 2012 51
Chipscreen Biosciences Ltd, H2 2012 52
ERYtech Pharma, H2 2012 53
Provecs Medical GmbH, H2 2012 54
Jennerex Biotherapeutics, Inc., H2 2012 55
Advenchen Laboratories, LLC, H2 2012 56
Onconova Therapeutics, Inc, H2 2012 57
MolMed S.p.A., H2 2012 58
China Medical System Holdings Limited, H2 2012 59
Welichem Biotech Inc., H2 2012 60
Oncolys BioPharma Inc., H2 2012 61
Immunocore Limited., H2 2012 62
Sirnaomics, Inc., H2 2012 63
Viventia Biotechnologies Inc., H2 2012 64
TRACON Pharmaceuticals, Inc., H2 2012 65
KAHR medical Ltd., H2 2012 66
Keystone Nano, Inc., H2 2012 67
EOS S.p.A., H2 2012 68
IkerChem S.L., H2 2012 69
Assessment by Monotherapy Products, H2 2012 70
Assessment by Combination Products, H2 2012 71
Assessment by Stage and Route of Administration, H2 2012 73
Assessment by Stage and Molecule Type, H2 2012 75
Liver Cancer Therapeutics Drug Profile Updates 101
Liver Cancer Therapeutics Discontinued Products 102
Liver Cancer Therapeutics Dormant Products 103
Liver Cancer Therapeutics Dormant Products (Contd..1) 104
Liver Cancer Therapeutics Dormant Products (Contd..2) 105
Liver Cancer Therapeutics Dormant Products (Contd..3) 106
Liver Cancer Therapeutics Dormant Products (Contd..4) 107
Liver Cancer Therapeutics Dormant Products (Contd..5) 108
Liver Cancer Therapeutics Dormant Products (Contd..6) 109
Number of Products under Development for Liver Cancer, H2 2012 11
Products under Development for Liver Cancer Comparative Analysis, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 17
Late Stage Products, H2 2012 22
Mid Clinical Stage Products, H2 2012 23
Early Clinical Stage Products, H2 2012 24
Discovery and Pre-Clinical Stage Products, H2 2012 25
Assessment by Monotherapy Products, H2 2012 70
Assessment by Combination Products, H2 2012 71
Assessment by Route of Administration, H2 2012 72
Assessment by Stage and Route of Administration, H2 2012 73
Assessment by Molecule Type, H2 2012 74
Assessment by Stage and Molecule Type, H2 2012 75